U.S. Markets closed

ClearPoint Neuro, Inc. (CLPT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
18.83+0.83 (+4.61%)
At close: 4:00PM EDT

18.83 0.00 (0.00%)
After hours: 7:21PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close18.00
Open18.48
Bid18.65 x 800
Ask18.83 x 900
Day's Range17.90 - 19.48
52 Week Range2.90 - 31.29
Volume279,251
Avg. Volume480,775
Market Cap386.252M
Beta (5Y Monthly)1.04
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMay 10, 2021 - May 14, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est35.00
  • ClearPoint Neuro, Inc. Announces Retirement of Director John N. Spencer, Jr.
    GlobeNewswire

    ClearPoint Neuro, Inc. Announces Retirement of Director John N. Spencer, Jr.

    SOLANA BEACH, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today the upcoming retirement of John N. Spencer, Jr. from its Board of Directors. Mr. Spencer, who has as served as a director since March 2010, is retiring when his current term of office expires effective at ClearPoint’s Annual Meeting of Stockholders to be held on June 3, 2021. “Jack has contributed substantially to the growth of our Company and will be missed,” commented Joe Burnett, President and CEO of ClearPoint Neuro. “He has been a steady force, helping to navigate this Company through difficult times over the last 11 years. I am thrilled that he is able to retire at a time when the Company is stronger than it has ever been before in its history.” “I enjoyed my 11 years on the Company’s Board immensely,” stated Mr. Spencer. “Nine months after joining the Board, ClearPoint had its first case, and, over the coming months, is expected to celebrate its 5,000th case. The Company’s growth, in both the types and number of cases, has given it preeminent status in its sectors of the medical device industry. ClearPoint proudly hires the best available talent and serves many prestigious hospitals.” About ClearPoint Neuro ClearPoint Neuro’s mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Company’s current product portfolio include deep brain stimulation, laser ablation, biopsy, neuro-aspiration, and delivery of drugs, biologics, and gene therapy to the brain. The ClearPoint Neuro Navigation System has FDA clearance, is CE-marked, and is installed in over 60 active clinical sites in the United States, Canada, and Europe. The Company’s SmartFlow® cannula is being used in partnership or evaluation with over 25 individual biologics and drug delivery companies in various stages – from preclinical research to late-stage regulatory trials. To date, more than 4,000 cases have been performed and supported by the Company’s field-based clinical specialist team, which offers support and services for our partners. For more information, please visit www.clearpointneuro.com. Forward-Looking Statements Statements herein concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the impact of COVID-19 and the measures adopted to contain its spread; future revenues from sales of the Company’s ClearPoint Neuro Navigation System products; and the Company’s ability to market, commercialize and achieve broader market acceptance for the Company’s ClearPoint Neuro Navigation System products. More detailed information on these and additional factors that could affect the Company’s actual results are described in the “Risk Factors” section in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, which has been filed with the Securities and Exchange Commission, and in the Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2021, which the Company intends to file with the Securities and Exchange Commission on or before May 17, 2021. CONTACT: Contact: Jacqueline Keller, Vice President, Marketing (949) 900-6833 jkeller@clearpointneuro.com Caroline Corner, Investor Relations ir@clearpointneuro.com

  • ClearPoint Neuro, Inc. Congratulates uniQure on Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
    GlobeNewswire

    ClearPoint Neuro, Inc. Congratulates uniQure on Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

    IRVINE, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates uniQure N.V. on the early completion of patient enrollment in the first dose cohort of a randomized, double-blinded, Phase I/II clinical trial of AMT-130 being conducted in the United States for the treatment of early-stage Huntington’s disease. Six patients out of ten who were enrolled in the first cohort were randomized to receive AMT-130 gene therapy and underwent administration procedures using the ClearPoint® Neuro Navigation System and SmartFlow® MRI-safe neuro ventricular cannulae under MRI guidance. The Company’s clinical specialist team provided support during the administration and imitation surgery (sham) procedures to assist the study team in executing the clinical trial protocol. A second, higher-dose cohort in this study is expected to begin enrolling 16 patients in the second half of 2021. A separate, open-label Phase Ib/II clinical trial of AMT-130 for 15 patients at European trial sites is expected to be performed using the ClearPoint Neuro Navigation System and SmartFlow cannulae, with patient enrollment planned to begin later this year. Huntington’s disease is a rare, inherited neurodegenerative disorder impacting approximately 70,000 people in the U.S. and Europe.1 It affects motor function and leads to behavioral symptoms and cognitive decline in young adults, resulting in total physical and mental deterioration. It is caused by the expansion of the CAG trinucleotide in exon 1 of a multifunctional gene coding for a protein called huntingtin. Despite the clear etiology of Huntington’s disease, there are no currently approved therapies to delay the onset or to slow disease progression. uniQure’s gene therapy product candidate AMT-130 consists of an AAV5 vector carrying a gene that expresses a micro-RNA specifically tailored to block the production of huntingtin protein, including the toxic mutant variant. Using AAV vectors to deliver this treatment directly to affected areas in the brain under live MRI-guidance for non-selective knockdown of the huntingtin mRNA represents a highly innovative and promising approach to treating Huntington’s disease. “ClearPoint is proud to help advance potential treatments for this devastating disorder,” stated Jeremy Stigall, Vice President, Biologics and Drug Delivery. “At this time, we are actively pursuing the installation process in Europe to prepare for training and enrollment of the new Phase Ib/II clinical trial sites in the second half of 2021.” About ClearPoint Neuro ClearPoint Neuro’s mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Company’s current product portfolio include deep brain stimulation, laser ablation, biopsy, neuro-aspiration, and delivery of drugs, biologics, and gene therapy to the brain. The ClearPoint Neuro Navigation System has FDA clearance, is CE-marked, and is installed in over 60 active clinical sites in the United States, Canada, and Europe. The Company’s SmartFlow® cannula is being used in partnership or evaluation with over 25 individual biologics and drug delivery companies in various stages – from preclinical research, to late-stage regulatory trials. To date, more than 4,000 cases have been performed and supported by the Company’s field-based clinical specialist team, which offers support and services for our partners. For more information, please visit www.clearpointneuro.com. Forward-Looking Statements Statements herein concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the impact of COVID-19 and the measures adopted to contain its spread; future revenues from sales of the Company’s ClearPoint Neuro Navigation System products; and the Company’s ability to market, commercialize and achieve broader market acceptance for the Company’s ClearPoint Neuro Navigation System products. More detailed information on these and additional factors that could affect the Company’s actual results are described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, which has been filed with the Securities and Exchange Commission. ________________________1 http://uniqure.com/gene-therapy/huntingtons-disease.php CONTACT: Contact: Jacqueline Keller, Vice President, Marketing (949) 900-6833 jkeller@clearpointneuro.com Caroline Corner, Investor Relations ir@clearpointneuro.com

  • ClearPoint Neuro, Inc. Announces Appointment of Ellisa Cholapranee as General Counsel
    GlobeNewswire

    ClearPoint Neuro, Inc. Announces Appointment of Ellisa Cholapranee as General Counsel

    Ellisa Cholapranee Ellisa Cholapranee IRVINE, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Ellisa Cholapranee will join the Company as General Counsel on April 5, 2021. Ms. Cholapranee will report directly to Joe Burnett, ClearPoint Neuro’s Chief Executive Officer, and serve as a member of the Company’s senior leadership team. “Ellisa is a tremendous addition to our capable and growing leadership team,” commented Joe Burnett, President and CEO of ClearPoint Neuro. “Not only does Ellisa offer the broad experience in compliance, contracting and strategy, but like our Company itself, she has experience in both medical devices and biologics and drug delivery. Her insight having worked extensively as a partner to the pharma industry will enhance communication and efficiency, both in signing new gene therapy and stem cell partners, as well as broaching more sophisticated risk sharing agreements with our collaborators.” Ms. Cholapranee brings to the Company almost a decade of experience advising companies in the life science and medical device sectors on legal, business, and compliance issues. Before joining the Company, she was Senior Legal Counsel for the cardiovascular devices division at Philips. Prior to that, Ms. Cholapranee served as Senior Corporate Counsel at MilliporeSigma, a global life science company focused on providing solutions to pharmaceutical companies in every step of the biotech production chain, from research to drug manufacturing. She also has several years’ experience in the corporate and financial services departments of leading law firms in Boston and Chicago, where she counseled clients in the areas of corporate law, public offerings, mergers and acquisitions, and venture capital. Ms. Cholapranee holds a Bachelor of Science in Mathematics from Carnegie Mellon University, and a J.D. from the Northwestern University Pritzker School of Law. “I am thrilled to join ClearPoint at such an exciting phase of the Company’s growth,” stated Ellisa Cholapranee. “ClearPoint’s technology and team are truly impressive. I look forward to helping build upon the many successes of the Company.” About ClearPoint Neuro ClearPoint Neuro’s mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Company’s current product portfolio include deep-brain stimulation, laser ablation, biopsy, neuro-aspiration, and delivery of drugs, biologics, and gene therapy to the brain. The ClearPoint Neuro Navigation System has FDA clearance, is CE-marked, and is installed in over 60 active clinical sites in the United States, Canada, and Europe. The Company’s SmartFlow® cannula is being used in partnership or evaluation with 25 individual biologics and drug delivery companies in various stages from preclinical research to late-stage regulatory trials. To date, more than 4,000 cases have been performed and supported by the Company’s field-based clinical specialist team which offers support and services for our partners. For more information, please visit www.clearpointneuro.com. Forward-Looking Statements Statements herein concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the impact of COVID-19 and the measures adopted to contain its spread; future revenues from sales of the Company’s ClearPoint Neuro Navigation System products; and the Company’s ability to market, commercialize and achieve broader market acceptance for the Company’s ClearPoint Neuro Navigation System products. More detailed information on these and additional factors that could affect the Company’s actual results are described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, which has been filed with the Securities and Exchange Commission.Contact: Jacqueline Keller, Vice President, Marketing(949) 900-6833info@clearpointneuro.com Caroline Corner, Investor Relationsir@clearpointneuro.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fbcbd8ad-a160-4fd1-ab3f-cdd745f12760.